← Back to Search

Bradykinin Receptor Antagonist

KVD900 600 mg for Hereditary Angioedema

Phase 3

Waitlist Available

Research Sponsored by KalVista Pharmaceuticals, Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 4 hours and within 12 hours of the first imp administration.

Awards & highlights

Study Summary

This trial is testing a new drug to treat hereditary angioedema, a condition that causes swelling. The trial is testing the drug's safety and effectiveness in adolescent and adult patients.

Eligible Conditions

Hereditary Angioedema

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 4 hours and within 12 hours of the first imp administration.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 4 hours and within 12 hours of the first imp administration.

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 4 hours and within 12 hours of the first imp administration. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to beginning of symptom relief Patient Global Impression of Change (PGI-C)

Secondary outcome measures

Proportion of attacks with beginning of symptom relief (PGI-C)

Time to HAE attack resolution (PGI-S)

Time to at least "better" (2 time points in a row) (PGI-C)

+3 more

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: KVD900 600 mgExperimental Treatment1 Intervention

Group II: KVD900 300 mgExperimental Treatment1 Intervention

Group III: PlaceboPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

KVD900 300 mg

2022

Completed Phase 3

~140

KVD900 600 mg

2022

Completed Phase 3

~140

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

KalVista Pharmaceuticals, Ltd.Lead Sponsor

9 Previous Clinical Trials

651 Total Patients Enrolled

Study DirectorStudy DirectorKalVista Pharmaceuticals, Ltd.

1,208 Previous Clinical Trials

489,559 Total Patients Enrolled

Media Library

KVD900 (Bradykinin Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05259917 — Phase 3

Hereditary Angioedema Research Study Groups: Placebo, KVD900 300 mg, KVD900 600 mg

Hereditary Angioedema Clinical Trial 2023: KVD900 Highlights & Side Effects. Trial Name: NCT05259917 — Phase 3

KVD900 (Bradykinin Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05259917 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is KVD900 600 mg a safe dosage for people?

"There is some evidence of efficacy and multiple safety data sets from Phase 3 trials, which gives KVD900 600 mg a safety rating of 3."

Answered by AI

Can more people participate in this experiment?

"That is accurate. The clinical trial in question, which was initially posted on February 23rd, 2022, is still seeking patients. A total of 114 individuals are needed for the 17 different enrolment sites."

Answered by AI

How many people are chosen to participate in this research project?

"The public information on clinicaltrials.gov verifies that this research is presently looking for individuals to participate. The study was initially posted on February 23rd, 2022 and was most recently updated on October 31st, 2022. There are 17 sites enrolling a total of 114 patients."

Answered by AI

At how many different sites can patients participate in this research?

"This trial is currently being run at 17 different sites. The sites are located in Chicago, Hershey, Scottsdale, and a few other locations. If you enroll in the trial, it is important to select the site nearest you to minimize travel demands."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

2022. "A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05259917.